Vijaya Diagnostic Centre Limited has informed the Exchange regarding Grant of 115000 Options.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre's board met on February 13, 2026 and approved several key decisions. The board noted Q3 and nine-month FY26 (ended December 31, 2025) unaudited financial results. Two new independent directors — Mr. Ravi Shankararamiah (a senior advocate with 40+ years in corporate/tax law) and Dr. Sasikala Paruchuri Kola (a senior gynaecologist) — were appointed for five-year terms, subject to shareholder approval. The existing CFO, Mr. S. Ramachandra Reddy, resigned due to organisational restructuring but will stay on as GM – Finance & Accounts. Mr. Ankit Shah (ex-Group CFO of Incor/OMNI Hospitals, a chartered accountant) was appointed as the new CFO, alongside a new CTO (Mr. Sai Siva Prasad, previously at UnitedHealth/Optum) and COO (Mr. Venkata Siva Rama Raju Vegesna, returning from KIMS Hospitals). The board also granted 1,15,000 ESOPs at ₹809 per share (a 20% discount to the three-month average closing price) and approved a revised Related Party Transactions policy in line with updated SEBI norms.
The change is significant at the top finance and operations levels — a new CFO plus a returning COO and a technology-focused CTO suggest the company is preparing for a growth or restructuring phase. Investors should watch the Q3 results for performance cues and note the 1,15,000 ESOP grant as a mild future dilution signal.